StemCell Therapy

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, published updated clinical data from the ongoing phase 2a study (HEP101) of its lead product candidate HepaStem in patients with Acute-on-Chronic Liver Failure (ACLF) or acute decompensation (AD) at high risk of developing ACLF. The data were presented in an oral presentation at the Annual Meeting of the American Association for Study of Liver Diseases (AASLD) on November 10, 2019, in Boston, by Prometheras principal investigator Prof. F. Nevens, KULeuven, Belgium. The data set confirmed earlier findings presented at The International Liver Congress - ILC 2019 in April.

Currently, liver transplant is the only rescue treatment for patients suffering from ACLF and to a lesser degree for patients with acute decompensation of the liver (AD). There are no other existing therapies that can rescue the end-stage-liver failure. Promethera is developing HepaStem as an alternative to transplant; it consists of liver derived stem cells that are obtained from ethically donated healthy human organs and expanded in GMP culture conditions. These liver derived signaling stem cells migrate through the blood stream to reach the liver, where they support the tissue regeneration via their potent secretome.

In the trial HEP101, HepaStem has been intravenously infused in single or repeated injections in multiple ascending doses in patients to assess the tolerability and the safety profile of the treatment. The trial which recruited a total of 24 patients, including 16 patients with ACLF and 8 patients with AD has met its primary endpoint.

With one or two repeated doses up to 1.2 million cells per kilogram of body weight, no adverse events related to HepaStem occurred and no clinically significant changes were shown in platelet count, fibrinogen levels, and coagulation factors following HepaStem infusion. The demonstrated safety of two infusions of 1.2 million cells per kilogram of body weight provide solid guidance for conducting the subsequent trials. In addition to the positive safety profile, the study has shown trends in efficacy with improvement in three indicators of liver disease severity; Model for End Stage Liver Disease score (MELD), Child-Pugh score and bilirubin levels, 28 days and three months after treatment initiation. Promethera plans to demonstrate the efficacy of HepaStem at 1.0 million cells per kilogram of body weight in ACLF with a large multicentric double blind placebo-controlled trial (HEP102). The study HEP102 is expected to start end 2019.

We continue to pioneer the use of liver stem cells for the treatment of severe liver diseases and the updated status from the worlds first clinical trial evaluating a cell-based therapy in ACLF gives us confidence about the safety aspects and the broad therapeutic potential of our therapy, said Etienne Sokal, M.D., Ph.D., Prometheras Group Chief Medical Officer. As a potential first tangible alternative to organ transplantation for an ever-growing patient population, HepaStem will advance into a larger efficacy trial in ACLF focusing on a reduced need for transplantation and a decreased mortality.

Prof. Nevens added, With the data set having evolved since we last presented results at this years ILC Congress, the Phase 2a trial provides a strong rationale for further clinical evaluation of the therapeutic concept and has provided a safe dosing regimen which will guide future studies.

About Promethera Biosciences

Promethera Biosciences is a global innovator in liver therapeutics whose mission is to bring life-saving treatments to reduce the need for liver transplantation. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties. In addition to our cell-based pipeline we develop antibody technologies, such as the antiTNF-R1 antibody Atrosimab, to complement and diversify our therapeutic options. We are a team of international experts operating out of facilities in Mont-Saint-Guibert, Belgium, Durham, NC, USA, Tokyo, Japan and Basel, Switzerland.

Promethera, HepaStem, H2stem, are all registered trademarks of the PROMETHERA group.

Originally posted here:
Promethera Biosciences Presents Updated Clinical Results at AASLD 2019 for World's First Stem Cell Therapy Trial using HepaStem in Acute-on-Chronic...

GlobalStem Cell TherapyMarket Overview:

We,MRInsights.biz, after comprehensive analysis, have introduced a new research study onGlobalStem Cell TherapyMarket. The report provides a unique, first-time market and competitive analysis of the size, segmentation, competition, trends, and outlook in the manufacturers operating in theStem Cell Therapymarket. The report comprises all analytical and statistical brief summary regarding market summary, growth, demand, and forecast analysis. It covers the key manufacturers profiles in detail along with market entry strategies, production analysis, market share, revenue forecast and regional analysis of the market. It particularly delivers delivering wide-ranging analytical information on regional segmentation.

The researchers team presents the analytical data and figures in the report in an effectual way with the help of graphs, diagrams, pie charts, and other pictorial illustrations. The report focuses on providing the clients and other readers with all the necessary information regardingStem Cell Therapymarket share, new product launch, applications, provinces, businesses, economic growth, and supply and demand rate.It examines the industry potentials for each geographical region with respect to the customer purchasing patterns, macroeconomic parameters, market demand and supply states, and growth rate.

DOWNLOAD FREE SAMPLE REPORT:https://www.mrinsights.biz/report-detail/179414/request-sample

Leading vendors covered in the report are:Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCRPharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix)

Growth Drivers And Industry Trends:

TheStem Cell Therapymarket is divided into different segments with reference to the geographic, types, applications, and manufacturers. Our team of researchers has followed a focused and realistic research outline in order to investigate the important market dynamics like drivers, restraints, and opportunities in many regions across the world.

Geographical Analysis:

The study details country-level aspects based on each segment and gives estimates in terms of market size. The key regional trends beneficial to the growth of theStem Cell Therapymarket are discussed. Further, it analyzes the market potential for every nation. Geographic segmentation covered in the market report:

ACCESS FULL REPORT:https://www.mrinsights.biz/report/global-stem-cell-therapy-market-growth-status-and-179414.html

What The GlobalStem Cell TherapyMarket Report Contains:

Research objectives

TheStem Cell Therapymarket size is calculable in terms of revenue (US$) and production volume during this report. Moreover, the study showcases back-to-back parameters like application, improvement, product growth, and diverse structures & key processes. The report delivers a perfect solution, which incorporates current market intelligence, future projections for the growth, technology inputs, and future market trends. Then it serves a market outlook for 20142024 and sets the forecast.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@mrinsights.biz), who will ensure that you get a report that suits your needs.Stem Cell Therapy

Go here to read the rest:
Global Stem Cell Therapy Market 2019 : Analysis and Market Expert Research Report Forecast to 2024 - Eastlake Times

The Global report titled on Stem Cell Therapy Market delivering key insights and providing a competitive advantage to clients through a detailed report. The report also details the information about the global market status, growth rate, future trends, market drivers, challenges, opportunities and porters forces analysis with respect to these elements. An exclusive data offered in this report is collected by research and industry experts team.

Get Free Sample Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=281584

The Global Stem Cell Therapy Market is estimated to grow at a CAGR of 11.0% during 2016 to 2021 to reach US$ 145.8 Million by 2021. This report spread across 120 Pages, Profiling 10 Companies and Supported with 60 Tables and 37 figures is now available in this research.

Top Companies profiled in the Stem Cell Therapy Market:

Growth in the global stem cell therapy market is driven by factors such as the growing awareness of the therapeutic potency of stem cells in effective disease management, development of advanced genome-based cell analysis techniques, increasing public-private investments for development of stem cell therapies, identification of new stem cell lines, and developments in infrastructure related to stem cell banking and processing. In addition, countries such as Japan, South Korea, and China are offering new growth opportunities for players operating in this market.

Premium Insights:

1 Stem Cell Therapy Market Overview

2 Regional Analysis: Market, By Type, 2016 vs 2021 (USD Million)

3 Global Market, By Therapeutic Application, 20162021 (USD Million)

4 Regional Analysis: Market, By Cell Source, 2016 vs 2021 (USD Million)

Check Discount Offers @ https://www.reportsnreports.com/contacts/discount.aspx?name=281584

Based on the type of therapy, the allogeneic stem cell therapy segment is estimated to command the larger share of the global stem cell therapy market in 2016. This growth can be attributed to the growing availability of allogeneic stem cell therapy products, wider therapeutic applications of allogeneic stem cells, easier production scale-up due to easy availability of sources of stem cells, and growing number of clinical trials of allogeneic stem cell therapies as compared to autologous stem cell therapies.

Competitive Landscape of Stem Cell Therapy Market:

1 Overview

2 Market Ranking

3 Strategic Benchmarking

3.1 Product Development and Commercialization

4 Competitive Scenario

5 Recent Developments

5.1 Product Launches and Approvals

5.2 Expansions

5.3 Agreements, Collaborations, and Partnerships

Ask Question @ https://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=281584

Reason to access this report:

From an insight perspective, this research report focuses on various levels of analysismarket share analysis of the top players and company profiles, which together comprise and discuss basic views on the competitive landscape; emerging and high-growth segments of the stem cell therapy market; and high-growth regions and their respective drivers, restraints, challenges, and opportunities.

Original post:
Stem Cell Therapy Market to Grow at 11.0% CAGR to 2021 - Weekly Spy

A leading research firm, Zion Market Research added a latest industry report on "Global Stem Cell Therapy Market" consisting of 110+ pages during the forecast period and Stem Cell Therapy Market report offers a comprehensive research updates and information related to market growth, demand, opportunities in the global Stem Cell Therapy Market.

According to the report the Stem Cell Therapy Market-Global and Regional Analysis by Top Key Industry Players, Key Regions, Product Segments, and Applications 2025

The Stem Cell Therapy Market report provides in-depth analysis and insights into developments impacting businesses and enterprises on global and regional level. The report covers the global Stem Cell Therapy Market performance in terms of revenue contribution from various segments and includes a detailed analysis of key trends, drivers, restraints, and opportunities influencing revenue growth of the global consumer electronics market.This report studies the global Stem Cell Therapy Market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the global Stem Cell Therapy Market by companies, region, type and end-use industry.

Request a Free Sample Report on Stem Cell Therapy Market: https://www.zionmarketresearch.com/sample/stem-cell-therapy-market

The Stem Cell Therapy Market report mainly includes the major company profiles with their annual sales & revenue, business strategies, company major products, profits, industry growth parameters, industry contribution on global and regional level.This report covers the global Stem Cell Therapy Market performance in terms of value and volume contribution. This section also includes major company analysis of key trends, drivers, restraints, challenges, and opportunities, which are influencing the global Stem Cell Therapy Market. Impact analysis of key growth drivers and restraints, based on the weighted average model, is included in this report to better equip clients with crystal clear decision-making insights.

The Stem Cell Therapy Market research report mainly segmented into types, applications and regions.The market overview section highlights the Stem Cell Therapy Market definition, taxonomy, and an overview of the parent market across the globe and region wise.To provide better understanding of the global Stem Cell Therapy Market, the report includes in-depth analysis of drivers, restraints, and trends in all major regions namely, Asia Pacific, North America, Europe, Latin America and the Middle East & Africa, which influence the current market scenario and future status of the global Stem Cell Therapy Market over the forecast period.

Get Free PDF Brochure of this Report: https://www.zionmarketresearch.com/requestbrochure/stem-cell-therapy-market

The Stem Cell Therapy Market report provides company market size, share analysis in order to give a broader overview of the key players in the market. Additionally, the report also includes key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, product and regional expansion of major participants involved in the market on the global and regional basis.

Major Company Profiles Covered in This Report:

Anterogen Co., Ltd., RTI SurgicalInc., Pharmicell Co., Ltd., MEDIPOST Co., Ltd., JCR Pharmaceuticals Co., Ltd., Holostem Terapie Avanzate S.r.l., NuVasiveInc., and AlloSource.

Some of the major objectives of this report:

1) To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the global Stem Cell Therapy Market.

2. To provide insights about factors affecting the market growth. To analyze the Stem Cell Therapy Market based on various factors- price analysis, supply chain analysis, porter five force analysis etc.

3. To provide historical and forecast revenue of the Stem Cell Therapy Market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, and Rest of the World.

4. Country level analysis of the market with respect to the current market size and future prospective.

5. To provide country level analysis of the market for segment by application, product type and sub-segments.

6. To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.

7. Track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Stem Cell Therapy Market.

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the clients needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to usafter allif you do well, a little of the light shines on us.

Contact Us:

Zion Market Research

244 Fifth Avenue, Suite N202

New York, 10001, United States

Tel: +49-322 210 92714

USA/Canada Toll Free No.1-855-465-4651

Email: sales@zionmarketresearch.com

Website: https://www.zionmarketresearch.com

As one of the lead news writers at zmr news reports, Hirens specialization lies in the science, technology, Health & business domains. His passion for the latest developments in cloud technology, connected devices, nanotechnology, and virtual reality, among others, shines through in the most recent industry coverage he provides. Hirens take on the impact of digital technologies across the technology, health and business domains gives his writing a fresh and modern outlook.

See the rest here:
Stem Cell Therapy Market-Global and Regional Analysis by Top Key Industry Players, Key Regions, Product Segments, and Applications 2025 - ZMR News...

NEW YORK, Nov. 7, 2019 /PRNewswire/ --

INTRODUCTIONAdvances in the fields of cell biology and regenerative medicine have led to the development of a variety of stem cell-based therapies for many cardiovascular, oncological, metabolic and musculoskeletal disorders. Driven by the revenues generated from stem cell therapies, the regenerative medicine market is anticipated to generate revenues worth USD 100 billion by 2030. With a promising pipeline of over 200 stem cell therapy candidates, it has become essential for developers to scale up the production of such therapeutic interventions. Given that stem cell therapy manufacturing requires highly regulated, state-of-the-art technologies, it is difficult for stakeholders to establish in-house expertise for large-scale manufacturing of stem cell therapies. As a result, stem cell therapy developers have begun outsourcing their manufacturing operations to contract manufacturing organizations (CMOs). Specifically, small and mid-sized players in this sector tend to outsource a substantial proportion of clinical and commercial-scale manufacturing processes to contract service providers. In addition, even big pharma players, with established in-house capabilities, are gradually entering into long-term business relationships with CMOs in order to optimize resource utilization and manage costs.

Read the full report: https://www.reportlinker.com/p05826166/?utm_source=PRN

According to a recent Nice Insight CDMO survey, about 55% of 700 respondents claimed to have collaborated with a contract service provider for clinical and commercial-scale product development requirements. Considering the prevalent trends, we believe that the stem cell therapy manufacturing market is poised to grow at a steady pace, driven by a robust pipeline of therapy candidates and technological advances aimed at mitigating challenges posed by conventional methods of production. Amidst tough competition, the availability of cutting-edge tools and technologies has emerged as a differentiating factor and is likely to grant a competitive advantage to certain CMOs over other players in the industry.

SCOPE OF THE REPORTThe "Stem Cell Therapies Contract Manufacturing Market, 2019 2030" report features an extensive study on contract service providers engaged in the development and manufacturing of stem cell therapies. The study features in-depth analyses, highlighting the capabilities of various stem cell therapy CMOs. Amongst other elements, the report includes:

A detailed review of the contract manufacturing landscape for stem cell therapies, featuring a comprehensive list of active CMOs and analysis based on a number of parameters, such as year of establishment, company size, geographical location, number of stem cell therapy manufacturing facilities, source of stem cells (allogenic and autologous), types of services offered (culture development, stem cell identification / validation, stem cell banking, cryopreservation, logistics, fill / finish and regulatory filings), scale of operation (preclinical, clinical and commercial), types of stem cells (adult, embryonic and induced pluripotent) and therapeutic area (oncology and non-oncology). An elaborate discussion of the various guidelines laid down by regulatory bodies related to stem cells and other cell-based therapies across various geographies, such as the North America (primarily the US), Europe and other regions. Elaborate profiles of the key players based in North America, Europe and Asia-Pacific that have a diverse range of capabilities for the development, manufacturing and packaging of stem cell therapies. Each profile includes an overview of the company, its financial performance (if available), information on service portfolio, stem cell therapy manufacturing facilities, and details on partnerships, recent developments and an informed future outlook. An analysis of the recent collaborations (signed since 2015) focused on the contract manufacturing of stem cell therapies, based on various parameters, such as year of agreement, type of agreement, scale of operation, source of stem cells used, types of stem cells and location of companies entering the partnership. An informed estimate of the annual demand for stem cell therapies in terms of area (in square feet) dedicated to stem-cell related operations, based on various parameters, such as target patient population, price of the therapy, dosing frequency and dose strength. A detailed capacity analysis, taking into consideration the manufacturing capacities of various stakeholders (small-sized, mid-sized and large CMOs) in the market, based on data gathered via secondary and primary research. It also provides the distribution of global stem cell therapy manufacturing capacity by company size (small-sized, mid-sized and large), and geography (North America, Europe and Asia-Pacific) and scale of operation (preclinical / clinical and commercial). A detailed analysis to understand the relationship between the demand and supply in this field, comparing the presence of stem cell therapy developers and the availability / capability of contract manufacturers across different geographies. An analysis to identify the key performance indicators for service providers active in the domain, based on the information gathered via secondary research and primary research.

One of the key objectives of the report was to estimate the future size of the market. Based on parameters, such as increase in number of clinical studies, target patient population, anticipated adoption of stem cell therapies and expected variation in manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the mid to long term, for the period 2019-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] source of stem cells (autologous and allogenic), [B] types of stem cells (adult, embryonic and induced pluripotent), [C] size of contract service provider company (small-sized, mid-sized and large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America, Europe and Asia and rest of the world). To account for the uncertainties associated with the manufacturing of stem cell therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

Arik Hasson, Executive VP Research and Development, Kadimastem Brian Dattilo Manager of Business Development, Waisman Biomanufacturing David Mckenna, Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota Fiona Bellot, Business Development Manager, Roslin Cell Therapies Gilles Devillers, General Manager, Bio Elpida Mathilde Girard, Department Leader, Cell Therapy Innovation and Development, YposKesi

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGYThe data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include Annual reports Investor presentations SEC filings Industry databases News releases from company websites Government policy documents Industry analysts' views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINESChapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the likely evolution of the stem cell therapy contract manufacturing market in the mid to long term.

Chapter 3 provides a brief introduction to the basic concepts related to stem cell therapies and the intricacies of their development and administration. In addition, it includes information on the various types of stem cell therapies (based on the source, potency and lineage of stem cells), modes of delivery and the disease indications targeted by such interventions. It also includes a discussion on the different manufacturing models (centralized and decentralized) that are used for the production of stem cell therapies, along with a list of advantages and disadvantages. Further, it provides details on the scalability of stem cell therapies. The chapter also includes a brief overview on the role of automation and supply chain management, with respect to stem cell therapies.

Chapter 4 provides a comprehensive overview of the global stem cell therapy contract manufacturing landscape. It includes information related to over 80 CMOs that are currently active in this domain. In addition, it features an in-depth analysis of the market, based on a number of parameters, such as the year of establishment, company size, geographical location, number of stem cell therapy manufacturing facilities, source of stem cells (allogenic and autologous), types of services offered (culture development, stem cell identification / validation, stem cell banking, cryopreservation, logistics, fill / finish and regulatory filings), scale of operation (preclinical, clinical and commercial), types of stem cells (adult, embryonic and induced pluripotent) and therapeutic area (oncology and non-oncology). In addition, the chapter presents a list of the in-house players involved in manufacturing of stem cell therapies.

Chapter 5 provides a detailed description on the regulatory landscape related to stem cells and cell therapies across various geographies, such as the North America (primarily the US), Europe and other regions. Further, it presents an analysis of the manufacturing facilities on the basis of certifications awarded (for contract manufacturing stem cell-based therapies) to individual sites by various regulatory bodies across the globe.

Chapter 6 provides detailed profiles of some of the key players that are active in the stem cell contract manufacturing market in North America. Each profile presents a brief overview of the company, financial information (if available), its contract service offerings highlighting the capabilities of stem cell therapy facilities, recent developments and an informed future outlook.

Chapter 7 provides detailed profiles of some of the key players that are active in the stem cell contract manufacturing market in emerging regions such as Europe and Asia-Pacific. Each profile presents a brief overview of the company, financial information (if available), its contract service offerings highlighting the capabilities of stem cell therapy facilities, recent developments and an informed future outlook.

Chapter 8 features an elaborate analysis and discussion on the collaborations and partnerships that have been inked amongst players, since 2015. It includes brief descriptions of the various partnership models (including acquisition, distribution agreement, licensing agreement, manufacturing, product development / commercialization, product development and manufacturing, process development and manufacturing, process development, R&D agreements, service alliance and others) that have been adopted by stakeholders in this domain. It also includes analysis based on year of agreement, type of agreement, scale of operation, source of stem cells used, types of stem cells and location of companies entering the partnership. Further, the chapter features a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 9 presents a detailed analysis to understand the relationship between the demand and supply in this field, comparing the presence of stem cell therapy developers and the availability / capability of contract manufacturers across different geographies. The chapter presents a list of stem cell therapies along with other details, such as stage of development, source of stem cell therapy and location of the developer.

Chapter 10 features an analysis of the global / regional capacity of contract manufacturers that are engaged in the manufacturing of stem cell therapy products. The analysis takes into consideration the individual development and manufacturing capacities of various stakeholders (small-sized, mid-sized, and large CMOs) in the market, using data from both secondary and primary research. The results of this analysis were used to establish an informed opinion on the stem cell therapy production capabilities of organizations across different types of organization (industry and non-industry), scale of operation (clinical and commercial), geographies (North America, EU, Asia Pacific and the rest of the world) and size of the organization (small-sized, mid-sized and large-sized organizations).

Chapter 11 features an illustrative view on the demand for stem cell therapies (both clinical and commercially available) in the market, offering an informed opinion on the required scale of supply (in terms of stem cell therapy manufacturing services). For the purpose of estimating the current clinical demand, we considered the active clinical studies of different types of stem cell therapies that have been registered since 2010. The data was analyzed on the basis of various parameters, such as number of annual clinical doses, trial location, leading industry / non-industry sponsors, and the enrolled patient population across different geographies. Further, in order to estimate the commercial demand, we considered the commercialized stem cell products, based on various parameters, such as target patient population, dosing frequency and dose strength.

Chapter 12 presents an insightful market forecast analysis, highlighting the likely growth of the stem cell contract manufacturing market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] source of stem cells (autologous and allogenic), [B] types of stem cells (adult, embryonic and induced pluripotent), [C] size of contract service provider company (small-sized, mid-sized and large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America, Europe and Asia and rest of the world).

Chapter 13 features an analysis on the key performance indicators of service providers based on the information available for top-ten (based on the annual revenues generated in 2017)

Chapter 14 is a summary of the entire report. It provides the key takeaways and presents our independent opinion on the stem cell therapies contract manufacturing market, based on the research and analysis described in the previous chapters. It also provides a recap of some of the upcoming future trends, which, we believe, are likely to influence the growth of stem cell therapy contract manufacturing market.

Chapter 15 features the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the stem cell therapy contract manufacturing domain. We have inputs from Arik Hasson (Executive VP Research and Development, Kadimastem), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing), David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota), Fiona Bellot (Business Development Manager, Roslin Cell Therapies), Gilles Devillers (General Manager, Bio Elpida) and Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi).

Chapter 16 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 17 is an appendix that provides the list of companies and organizations mentioned in the report.

Read the full report: https://www.reportlinker.com/p05826166/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/stem-cell-therapy-contract-manufacturing-market-2019-2030-300953687.html

SOURCE Reportlinker

More here:
Stem Cell Therapy Contract Manufacturing Market, 2019-2030 - P&T Community

Arizona has been called "the wild, wild west" of regenerative medicine.

The Valley is one of the most popular places in the country for stem cell clinics. The new and controversial therapy is being marketed and practiced all over Phoenix and Scottsdale.

The less invasive procedure promises to heal pain, nearly anywhere in their body. It is advertised as effective, safe, and ethical, but outside experts and industry insiders say consumers need to do their research to avoid being exploited, and potentially spending thousands in cash on a worthless injection.

"IT HAS GREAT POTENTIAL"

The world of regenerative medicine is still being explored and developed.

"It actually gives you really good results," explained Dr. Matthew Hernandez, a naturopathic physician with Ethos.

"There's a lot of hope and promise, generally around the prospects for stem cells," said ASU Professor Emma Frow.

"Were still in the developmental stage. Stem cell therapy has been around for less than ten years. Thats new in medicine," said Dr. Steven Sorr, a naturopathic physician who runs Source of Health in Scottsdale.

"It encourages your own body to heal itself," said Janet McConnell, a 63-year-old bodybuilder who "had cartilage damage several years ago."

Instead of a surgery that would have derailed her competition training for months, she opted for injections.

"Three years ago, instead of the surgery, I had a PRP treatment," said McConnell. "It was very effective."

Years later, she returned to Dr. Hernandez for another round.

For most, Stem Cell and Platelet Rich Plasma (PRP) therapy is a mystery. "It's kind of controversial and experimental," said Matthew Riddle, Director of Sales for Celling Biosciences.

The treatments concentrate platelets or stem cells, usually from the patient's own blood. Experts say it is important to always ask the doctor or provider where the "growth factors" are coming from, because in order to ensure they are alive they should be coming from the patient's own blood, fat, or bone marrow. Otherwise, patients can receive "dead" stem cells, which are not nearly as effective.

"We are very adamant to use the patient's own cells," said Riddle, who uses a centrifuge to separate out the blood, saline and growth factors that will be re-injected. "When we inject that into an area, we are telling your body to go heal that spot," said Dr. Hernandez.

"Stem cell treatment is really about trying to take the stem cells out of your body and...inject them back into another part of your body, in order to try and heal whatever part of the body is suffering," said Professor Frow.

"IT'S THE NEW WAVE"

According to researchers, Scottsdale and Phoenix are two of the seven "hot spot" cities in the country.

Arizona State University professors Emma Frow and Dave Brafman spent years studying the industry , and mapping out dozens of clinics in the Valley. They believe there are many more, as some intentionally practice under the radar. "I don't believe right now that there is enough evidence to suggest that they work," said Professor Frow.

"They are unregulated, unproven and for-profit," added Professor Brafman.

The profits are plentiful. "There's cash involved, so this isn't covered by insurance," said Dr. Hernandez.

"PREYING ON PEOPLE'S PAIN"

The thousands in cash is one of many reasons the burgeoning industry is ripe for exploitation.

"The other piece too, it is it is new and upcoming," said Dr. Hernandez.

Many potential patients do not know the first thing about the procedure they are being sold, and doctors say many fall for sales tactics that are practiced at traveling seminars.

"They are preying on people's pain," said Dr. Sorr. "I think its really unethical and it upsets me."

Dr. Sorr believes the seminars are "a scam" that specifically targets an elderly clientele.

"They wine you and dine you. They go through a little dinner presentation and it is not the doctor, it's a marketing agency," he said.

The doctor told ABC15 he has had clients who have been duped, even after he told them they were not ideal candidates for stem cell or PRP therapy.

"It really broke my heart that he spent thousands upon thousands of dollars for something that was worthless.

"I don't agree with how they are done," said Dr. Hernandez. "They inject people and they get money. That's not practicing medicine, that is selling."

Both naturopathic physicians told ABC15 that some patients do not need the treatment, or will get subpar results from the injections. They say it is well known in the industry that some practices will continue to sell in order to reap the thousands in cash.

"ALL OF IT FALLS ON THE PATIENT"

Right now, there is little regulation or oversight of the industry in Arizona.

"Really all of it the falls on the patient, with very little recourse if things go wrong," said Dr. Emma Frow.

During the course of our investigation, ABC15 discovered the Arizona Medical Board and County Health Department do not take complaints or oversee the people performing injections. The federal government has also been slow to implement widespread regulation.

"The FDA has their hands tied," said Dr. Sorr. "There are too many people out there that are doing this that havent had the proper training, they dont have the right experience, the right tools and all that."

There are some larger regulations in Arizona, governing who can handle a needle and perform injections.

Unlike other industries though, including massage therapy, there is no board that checks on licensing or investigates complaints involving botched procedures or alleged fraud.

"The state medical boards, need to become a little bit more involved in sort of identifying, or responding to claims," said Professor Brafman.

"I don't think it would hurt to have it, for sure. At the end of the day it's about protecting the public," said Dr. Hernandez.

For thousands of Arizonans, like Janet McConnell, regenerative medicine has helped heal chronic pain. Before spending thousands thousands though, do your research. "Always get a second opinion," said Dr. Sorr.

"I think this is really a case of buyer beware, or consumer beware," said Professor Frow.

If you are planning on undergoing a stem cell or PRP treatment, click here for questions experts say you should always ask ahead of time.

See the article here:
Arizona the "wild west" of stem cell therapy; experts say promising therapy ripe for exploitation - ABC15 Arizona

NEW YORK and SHANGHAI, Nov. 6, 2019 /PRNewswire/ --Cellular Biomedicine Group Inc.(NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today reported its financial results and business highlights for the third quarter of 2019.

"During the third quarter of 2019, we made great strides in both corporate and clinical progress. We started our U.S. expansion for research and clinical development in a new 22,000 square foot facility in Rockville, Maryland in October 2019. This milestone will allow us to foster strategic partnerships, develop new innovations and support continued development of CBMG's cell therapy-based immune-oncology assets that have shown promise in early proof-of-concept trials in China," said Tony (Bizuo) Liu, Chief Executive Officer for the Company.

"We also had continued progress on the clinical side, with the initiation of our Phase II clinical trial in China of AlloJoin therapy for knee osteoarthritis (KOA). Additionally, our autologous stem cell therapy program for KOA, ReJoin, was accepted by the NMPA in China to begin a Phase II clinical trial. We are excited about our regenerative medicine programs as we are currently the only company that has received two clinical trial acceptances for any stem cell program in China."

Mr. Liu continued, "Presentations of our pre-clinical and clinical data at upcoming medical conferences later this year will demonstrate continued focus on our immune-oncology pipeline and we are proud to provide an update of our commitment to cancer immunotherapy."

Third Quarter 2019 and Other Recent Corporate Developments

Upcoming Clinical and Preclinical Presentations:

Financial Results for the Third Quarter of 2019

Conference Call and Webcast InformationThe Company will host a conference call and webcast with the investment community on Wednesday, November 6th at 4:30 p.m. Eastern Time featuring remarks by Tony Liu, Executive Director, CEO and CFO of CBMG.

Live Call:

Toll-Free: 1-855-327-6838

International: 1-604-235-2082

Webcast:

http://public.viavid.com/index.php?id=136796

Replay:

Toll-Free: 1-844-512-2921

International: 1-412-317-6671

Conference ID: 10007976

(Available approximately two hours after the completion of the live call until 11:59 p.m. ET on November 20, 2019)

About Cellular Biomedicine GroupCellular Biomedicine Group, Inc. (NASDAQ: CBMG) develops proprietary cell therapies for the treatment of cancer and degenerative diseases. It conducts immuno-oncology and stem cell clinical trials in China using products from its integrated GMP laboratory. The Company's GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards. Its Shanghai facility includes a "Joint Laboratory of Cell Therapy" with GE Healthcare and a "Joint Cell Therapy Technology Innovation and Application Center" with Thermo Fisher Scientific, which partnerships focus on improving manufacturing processes for cell therapies. CBMG currently has ongoing CAR-T Phase I clinical trials in China. The China NMPA (formerly CFDA) accepted the Company's IND application for a Phase II trial for AlloJoin, CBMG's "Off-the-Shelf" allogenic haMPC therapy for the treatment of Knee Osteoarthritis (KOA), and the Company's IND application for a Phase II trial for ReJoin autologous haMPC therapy for the treatment of KOA. CBMG is included in the broad-market Russell 3000 Index and the small-cap Russell 2000 Index, and the Loncar China BioPharma index. To learn more about CBMG, please visit http://www.cellbiomedgroup.com.

Forward-Looking StatementsStatements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include those regarding our ability to implement our plans, strategies and objectives for future operations, including regulatory approval of our IND applications, our plan to configure part of our Shanghai facility with GE Healthcare's FlexFactory platform, our ability to execute on our obligations under the terms of our licensing and collaboration arrangement with Novartis, our ability to execute on proposed new products, services or development thereof, results of our clinical research and development, regulatory infrastructure governing cell therapy and cellular biopharmaceuticals, our ability to enter into agreements with any necessary manufacturing, marketing and/or distribution partners for purposes of commercialization, our ability to seek intellectual property rights for our product candidates, competition in the industry in which we operate, overall market conditions, any statements or assumptions underlying any of the foregoing and other risks detailed from time to time in CBMG's reports filed with the Securities and Exchange Commission, Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

For more information, please contact:

Company Contact:Derrick C. LiHead of Strategy and Investor Relations, CBMGPhone: 917-717-0994Email: derrick.li@cellbiomedgroup.com

Investor Contact:Valter Pinto / Allison SossKCSA Strategic CommunicationsPhone: 212-896-1254 / 212-896-1267Email: cellbiomed@kcsa.com

CELLULAR BIOMEDICINE GROUP, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

September 30,

December 31,

2019

2018

Assets

Cash and cash equivalents

$29,035,677

$52,812,880

Restricted cash

17,000,000

-

Accounts receivable, less allowance for doubtful accounts of nil and $94,868 as of September 30, 2019 and December 31, 2018, respectively

-

787

Other receivables

591,271

101,909

Prepaid expenses

1,589,479

1,692,135

Total current assets

48,216,427

54,607,711

Investments

240,000

240,000

Property, plant and equipment, net

19,856,287

15,193,761

Right of use

14,298,613

15,938,203

Goodwill

7,678,789

7,678,789

Intangibles, net

7,521,523

7,970,692

Long-term prepaid expenses and other assets

7,640,535

5,952,193

Total assets

$105,452,174

$107,581,349

Liabilities and Stockholders' Equity

Liabilities:

Short-term debt

$14,138,419

$-

Accounts payable

5,686,023

422,752

Accrued expenses

1,477,174

1,878,926

Taxes payable

28,625

28,950

Other current liabilities

4,526,594

5,710,578

Total current liabilities

25,856,835

8,041,206

Other non-current liabilities

12,545,245

14,321,751

Total liabilities

38,402,080

22,362,957

Stockholders' equity:

Preferred stock, par value $.001, 50,000,000 shares authorized; none issued and outstanding as of September 30, 2019 and December 31, 2018, respectively

-

-

Visit link:
Cellular Biomedicine Group Reports Third Quarter of 2019 Financial Results and Business Highlights - P&T Community

Dr Bright, who voluntarily surrendered his registration on August 31, was banned from reapplying for seven years.

He was also ordered to pay the costs of the Health Care Complaints Commission (HCCC), which filed the complaints against him in January.

Dr Bright founded Macquarie Stem Cells in Liverpool, which on its website spruiks its experimental treatments as "lead[ing] the way" and "our way of giving back to the community".

Dr Bright was referred to the HCCC by deputy state coroner Hugh Dillon in 2016 over the "preventable" and "unnecessary" death of an elderly patient after an experimental liposuction stem cell procedure to treat her dementia.

The coroner found the 75-year old died due to a "cluster of errors", including a failure to stop taking blood thinning medication prior to surgery, resulting in uncontrolled blood loss.

The tribunal agreed with Coroner Dillon that the treatment bore the hallmarks of "quack medicine".

It also accepted the evidence of Professor Colin Masters from the University of Melbourne, who said there was no evidence stem cell therapy for dementia patients was safe and it was "completely inappropriate and unethical" on a person who was frail, in poor health and in an advanced stage of dementia.

The tribunal found no proper therapeutic basis for Dr Bright administering the same stem cell treatment on a "very vulnerable" patient suffering bilateral vestibular deficiency, a condition where there is difficulty maintaining balance.

The tribunal accepted the patient - who was allegedly told by Dr Bright the procedure was "100 per cent safe" - has been adversely impacted.

The other complaints upheld related to Dr Bright's prescribing of peptides to three patients, including a woman with terminal motor neurone disease.

The tribunal found Dr Bright did not conduct a proper assessment on a patient before prescribing peptides and failed to take adequate steps to obtain informed consent, including an acknowledgement of the lack of clinical data proving the effectiveness of peptides and potential side effects.

Dr Bright's extensive self-prescribing of peptides was "improper and unethical", the tribunal found.

Dr Bright denied the allegations through his lawyers earlier in the year, but instructed his legal team to cease acting for him in August.

He did not attend the tribunal's hearing and did not respond to the orders it handed down.

Carrie Fellner is an investigative reporter for The Sydney Morning Herald.

See the original post:
Surgeon banned over 'quack' procedures and 'reckless disregard' for safety - Sydney Morning Herald

Many for-profit stem cell clinics advertise therapies that are not backed by science and may actually cause harm.

For-profit stem cell clinics have popped up around California in recent years, advertising that they can treat everything from arthritis to Alzheimers, without FDA approval.

They claim that injections of stem cells (naturally occurring blank slate cells that can grow into any type of cell) can help alleviate pain or illness by replacing or regenerating diseased tissue claims that are not supported by existing research. The procedures can cost thousands of dollars out-of-pocket, and regulators have warned that patients have developed tumors, suffered infections and even lost eyesight after unapproved procedures.

No one knows how many clinics there are, but California reportedly has more than any other state. We asked Arnold Kriegstein, MD, PhD, director of the UC San Francisco Developmental & Stem Cell Biology Program, about whats real and whats not in stem cell medicine.

How do these clinics operate?

There has been an explosion of so-called clinics offering stem cell treatments for a wide range of ailments, none of which have been shown to be effective. They are largely unregulated. Many clinics claim that they can treat untreatable illnesses like Alzheimer's disease, autism, muscular dystrophy, or stroke. The list is quite extensive.

The majority are using fat tissue for their stem cells, obtained through liposuction. These are usually autologous cells, which means that they are taking the patient's own tissue and extracting cells to re-administer to the same patient, usually through an intravenous route. In addition to fat cells, some clinics administer bone marrow stem cells or umbilical cord or placental stem cells, which come from unrelated donors.

The clinics often advertise through testimonials from patients who've received their therapies. Many of the conditions that the testimonials address are the kinds that normally improve or fluctuate over time, such as joint pain, low back pain, arthritis, or multiple sclerosis.

The problem is that patients will receive a treatment, and then, within a month or two, they'll notice that the aches and pains in the joints are improving, and they will attribute the improvement to the stem cell therapy, when in fact it would've happened regardless.

What is the risk of trying an unproven stem cell treatment?

Reports of physical harm have included infections and the development of tumors. When using cells that are not the patients own, umbilical cord cells for example, immune responses can occur often triggering inflammatory conditions.

In cases where stem cells have been delivered into the eye, blindness has been reported, and when they have been delivered to the central nervous system through lumbar puncture (spinal tap), adverse outcomes including serious infections of the central nervous system and tumors have occurred.

Then there's the emotional cost associated with raising false hope, and the financial loss that comes from exorbitant fees charged for ineffective, potentially harmful therapies.

Why arent there more legitimate stem cell therapies available?

Stem cells have been in the news so much over the last decade or so that I think it has created the impression that therapies are already on the market. The reality is that it is very early days for the science. The most interesting, most promising animal studies are only now beginning to be translated into clinical trials, and the process for approval of therapies takes many years and very few are likely to succeed.

Unfortunately, the public needs to be patient, but the good news is that potential treatments are progressing along the pipeline.

What are some examples of proven stem cell therapies?

For the last 50 years or so, there have been countless patients successfully treated with hematopoietic stem cells, commonly known as bone marrow transplants. This remains the prototype for how a stem cell therapy can work. Other successful examples include corneal stem cell grafts for certain eye conditions, and skin grafts for burn victims.

There are efforts to see if stem cells could successfully treat diseases like Parkinson's and diabetes, particularly type 1 diabetes. There are clinical trials testing whether stem cell therapy might work against macular degeneration, a blinding disease that is very common as people age. There are also early stage clinical trials for nervous system disorders including stroke, spinal cord injury, and ALS (Lou Gehrigs disease).

All of these examples are still at a very early stage, where the primary goal is to make sure that the approaches are safe. To determine if they are effective will require large, well-controlled, relatively long-term clinical trials.

What will it take to advance stem cell therapy into more real treatments?

This is where basic research comes in. The field is evolving quickly, there's much to be done, and there's still a huge amount of promise in stem cell therapies down the road. But it's going to take a lot of very careful and very laborious research before we get there.

Read more here:
Stem Cell Therapy: What's Real and What's Not at California's For-Profit Clinics - UCSF News Services

Imagine youre a smiley-faced, feathery-gilled Mexican salamander called an axolotl. Youve just been born, along with hundreds of brothers and sisters. But salamanders like you live in the wild only in one lake near Mexico City, and that habitat isnt big enough for all of you. Theres not enough food. Only the strongest can survive. What do you do?

If youre an axolotl, you have two choiceseat your siblings arms, or have your arms eaten.

But even if you are the unfortunate victim of this sibling violence, not all hope is lost. In a few months, youll grow a whole new armbones, muscle, skin, nerves and all.

Its pretty gruesome, but cannibalism is a possible reason why they grow their arms back, says associate biology professor James Monaghan. His lab studies regeneration in axolotls, a peculiar species that can grow back limbs and other organs to various degrees.

When an injury occurs, some cues are released in that animal that tells cells near the injury to go from a resting state into a regenerative state, Monaghan says.

His lab is trying to figure out what those cues are, and how we might induce that response in humans, who have very limited regenerative abilities.

Humans are notoriously bad at regenerating, Monaghan says. After were done growing, the genes that tell our cells to grow new organs are turned off.

Thats a good thing because otherwise itd be chaos, he says. No one wants to spontaneously grow an extra finger.

Axolotls can turn back on those genes that we turn off permanently, Monaghan says.

Understanding the specific mechanisms that induce regenerative responses in axolotls is no small task since axolotls have the largest genome ever sequenced.

So far, the lab has identified one molecule, neuregulin-1, which is essential for regeneration of limbs, lungs, and possibly hearts.

When we removed it, regeneration stopped. And when we added it back in, it induced the regenerative response, Monaghan says. Im not saying its a golden bullet for inducing regeneration in humans, too, but it could be part of the puzzle.

A lot of researchers study limb regeneration in axolotls. But Monaghans lab is interested in extending this research to other organs, as well.

When you think of the human condition, most of our issues with disease are with internal organs, Monaghan says.

Take retina regeneration, for example. Monaghan says we can either learn the process axolotls undergo that allows their specialized cells to return back to developmental cells, and then mimic that process in human eyes. Or, we can learn which elements of the axolotl enable their cells to behave this way, and then add those elements to human stem cell therapy.

To test the latter, Monaghan has teamed up with a Northeastern associate professor of chemical engineering, Rebecca Carrier, and her lab to figure out the best way to transplant mammalian retinal cells using molecules found in the axolotl.

In the experiment, Monaghan and Carrier used pig eyes, which are similar to human eyes. When they transplanted stem cells from the retina of one pig into the retina of another, 99 percent of the transplanted cells died. Somethings missing, Monaghan says. The cells dont have the right cues.

But when Carrier and Monaghan injected those same pig stem cells into the axolotl eye, fewer cells died. They were much happier, Monaghan says. Theres something in the axolotl retina that the mammalian cells like.

One reason axolotls are so good at receiving transplants is because, unlike humans, they dont have a learned immune system, meaning they cant distinguish between themselves and foreign entities.

Its really easy to do grafts between animals because the axolotls cant tell that the new tissue isnt theirs, he says. They dont reject it like we might.

An obvious example of this can be seen in axolotls that are genetically modified with a green fluorescent protein found in jellyfish. These naturally white axolotls glow neon green in certain lighting.

With this we can ask really basic questions, like do cells change their fate when they participate in regeneration? Monaghan says.

For example, if Monaghan grafts muscle tissue from a green fluorescent animal onto a white axolotl and then that axolotl regenerates, does the axolotl grow green muscle? Do its bones glow green, too? What about its skin?

Researchers have found, however, that cells dont actually change. Green muscle yields green muscle only.

The axolotl isnt the only animal that can regrow organs. Starfish, worms, frogs, and other species of salamanders can also regenerate. But axolotls are special because, unlike other animals, they can regrow organs that are just as robust as the originals, no matter how old they get.

For example, tadpoles can regenerate limbs. But once they undergo metamorphosis and become frogs, they can only regrow a spike, Monaghan says. They lose the ability to grow back their digits.

The axolotls ability to fully regrow organs, even as it ages, could be partially due to its perpetual juvenile state. Axolotls, unlike most other amphibians, dont undergo metamorphosis naturally, which means they never technically reach adulthood, even though they can reproduce. This condition is called neoteny.

Axolotls come from a species that used to walk on land, Monaghan says. They do have legs, after all. But some mutation occurred that keeps them in the lake and from reaching adulthood.

To test whether their neotenic state is responsible for their ability to regenerate, Monaghan took a group of axolotl siblings and induced metamorphosis in one half by exposing them to thyroid hormones, a chemical that flips on the maturity switch in these amphibians. The other half was kept in the juvenile state.

In the experiment, the juveniles regenerated normally, but all of their adult siblings regenerated slower than usual, and had deformities in their regrown limbs.

There is some association with neoteny and the ability to regenerate, Monaghan says. But its not the main factor.

That main factor is yet to be discovered. But even though some of this might sound like science fiction, you already made an arm once, Monaghan says. If we could just learn how to turn back on those programs, our bodies might do the rest of the work.

For media inquiries, please contact media@northeastern.edu.

Read the rest here:
Meet the axolotl: A cannibalistic salamander that regenerates its limbs and might help us better understand human stem cell therapy -...

Theres a new frontier in medicine that seeks to cure not just treat symptoms by regenerating healthy tissue destroyed by disease.

In the firing line are currently incurable diseases that impose enormous suffering, debilitation and costs. This includes the muscle wasting inflicted by muscular dystrophy, for example, or the loss of brain neural cells in the case of Parkinsons disease.

Its the latter that the startup Convalesce Inc is primarily targeting, based on the development of a self-assembling and self-repairing material called AmGel. It contains nanofibres capable of nurturing stem cells to replace damaged nerves a function that can make or break the use of stem cells therapeutically.

To get all the interacting factors right meant drawing on nanotechnology, bioengineering, cell biology, developmental biology and material science super-advanced stuff.

AmGels development and commercialisation, however, owes a great deal to a new model for producing the next generation of innovators in this case, Convalesces co-founder, Dr Subhadeep Das.

He graduated with a PhD in 2017 from an academy specifically established to use advanced multidisciplinary research techniques to address critical global challenges, including in energy, infrastructure and manufacturing. Called the IITB-Monash Research Academy, its a joint venture between the Indian Institute of Technology Bombay (IITB) and Monash University.

Speaking from the prestigious IndieBio accelerator program in San Francisco, Das explains that stem cell technology perfectly fits the academys mission. These are cells that are potentially game-changing for medicine, yet their use is held back by the cells complex relationship to its molecular, cellular and extra-cellular environment.

You cant just inject stem cells into inflamed and damaged tissue. They dont survive in that micro environment, Das says. The solution requires drawing on multiple disciplines like having smaller pieces for a jigsaw puzzle.

For Parkinsons disease, that involves understanding the biophysicality of the brain and the dimensions and topography of its subcellular structures. This has led to the designing of nanofibres that form a scaffold for stem cells to attach and grow into. This matrix also cues stem cell growth and development into functioning nerve cells.

To get all the interacting factors right meant drawing on nanotechnology, bioengineering, cell biology, developmental biology and material science super-advanced stuff, Das says.

The science, however, is just the first step towards a cure. Convalesce constitutes the second phase meeting the testing, regulatory and commercialisation hurdles needed to get a viable therapy to patients.

Das admits the learning curve has been steep in the segue from research to commercialisation. Working alone, he might not have succeeded.

Instead, he took advantage of ongoing support provided by the IITB-Monash Research Academy, including the provision of exclusive rights to the intellectual property for AmGel, and mentoring from across both universities, especially from the academys CEO, Professor Murali Sastry.

He discovered that while starting a company is tough, there are people who are willing to help if you reach out. Its making the connections in the first place that matters.

On that score, the Monash alumni office do a great job. They provided us with introductions to alumni that included highly successful entrepreneurs and heads of venture firms. These are people who are willing to help because of the connection with Monash University.

Continue reading here:
Repairing the brain through stem cell therapy - Monash Lens

MIAMI, Oct. 24, 2019 /PRNewswire/ -- The AASCP has recently created guidelines thatare current safety recommendations given to physicians who are using biologics in their medical practice. A highly anticipated and sought after Safety StandardsPanel session, hosted by AASCP on Nov. 2, 2019, will be moderated by The Alliance for Cell Therapy Now,with President Ms. Janet Marchbrody.The sessions normally are closed to the public but this particular SafetyStandard Panel discussion will be open to the public, covering the growing safety concerns of the industry.

Alliance for Cell Therapy Now is a coalition of organizations representing patients, health care providers and the academic and scientific community, who are working together to advance safe and effective regenerative cell therapies. The mission is to advance the development, manufacturing and delivery of safe and effective regenerative cell therapies through policy development, consensus and advocacy. Alliance for Cell Therapy Now is bringing together experts and stakeholders to gain consensus on and advocate for policies that will advance the science and the field, including those focused on promoting clinical research, assuring the adoption of consensus standards to promote safety and quality, building capacity and expertise within the workforce, and establishing a national outcomes database to advance the science, promote improvements in quality and safety, and inform regulatory, paymentand patient decision-making.

Alliance for Cell Therapy Now is guided by an Advisory Board comprised of leaders in the scientific, academicand patient communities; Ms.Janet M. MarchibrodaPresident, Alliance for Cell Therapy Now Fellow, Bipartisan Policy Center Senior Vice President, Health Policy, Bockorny Group, has agreed to join theAASCP as a moderator for their SafetyPanelat The Hyatt Regency in Miami. This particular coveted safetypanel session will be open to the public and broadcast live on YouTube at 3:00 p.m. on Nov. 2, 2019.

According to AASCP, if you are using biologics in your practice, whether you are using SVF, PRP, bone marrow, UCB, amniotic products,exosomes,xenografts, or peptides, there are key considerations to take into account to achieve the best safety for your patients. The AASCP also recommends communication with the Chief Scientific Officer from the laboratory you work with.AASCP advises that just talking to a sales agent is not sufficient enough when determining the quality of products for your patients. Sales agents typically do not have a medical or scientific background.

The spokesman for the AASCP, Dr. AJFarshchian,said earlier: "The American Academy of Stem Cell Physicians is a group of physicians, scientists and researchers who collectively represent the most authoritativenon-federal group advocating for guidelines and education on stem cell therapy and regenerative medicine. AASCP members are experts within all fields of stem cell therapy from: SVF, BM, UCB, Exosomes, Peptides, Xenografts, Allografts and Amniotic Fluids and are considered the most experienced leaders for proper advocacy in the field. The AASCP is involved directly with other authorities within the field and seeks only to bring knowledge and awareness for the ever growing regenerative medicine industry.My hope is that the SafetyPanel discussion on Nov.2, 2019, is to help get rid of the bad actors that are damaging the field for everyone."

AASCP is hosting their medical conference in Miami on Nov. 1-3 , 2019. Sessions are normally closed to the public and, therefore, require registration. The conference is taking place at the downtown MiamiHyatt Regency, located at 400 SE 2nd Ave, Miami, FL 33131.Becauseof limited seating, we encourage everyone to please RSVP ataascp.net andto register.

The American Academy of Stem Cell Physicians (AASCP) is an organization created to advance research and the development of therapeutics in regenerative medicine, including diagnosis, treatmentand prevention of disease related to or occurring within the human body. Secondarily, the AASCP aims to serve as an educational resource for physicians, scientistsand the public in diseases that can be caused by physiological dysfunction that areameliorableto medical treatment.

For further information, please contact Marie Barbaat AASCP 305-891-4686 and you can also visit us at http://www.aascp.net.

Related Images

dr-farshchian-teaching-at-aaoscp.jpeg Dr. Farshchian teaching at AAOSCP workshop Dr. Alimorad Farshchian speaking at AASCP

Related Links

AASCP Safety guidelines

AASCP website / registration

View original content to download multimedia:http://www.prnewswire.com/news-releases/american-academy-of-stem-cell-physicians-announced-today-that-their-safety-panel-session-is-open-and-free-to-the-public-300945080.html

SOURCE The American Academy of Stem Cell Physicians

View original post here:
American Academy of Stem Cell Physicians Announced Today That Their Safety Panel Session is Open and Free to the Public - P&T Community

Winter is a lot of things: cold, icy and dark, just to name a few. Its not typically the time of year for Northeastern Minnesotans to try to initiate lifestyle changes that can lead to improved health. Most people would prefer to layer up and hunker in for the cold months ahead.

However, the Hibbing Area Chamber of Commerce is looking to change that with their inaugural Health and Wellness Fair. The free event is slated to run from 9 a.m. to 2 p.m. at the Hibbing Memorial Building on Saturday, Oct. 26. The idea is to help area residents take charge of all aspects of their health before the winter doldrums can strike.

Local business owner, Paula VanBaalen is the chair of the Hibbing Health and Wellness committee and serves as a board member for the Hibbing Area Chamber of Commerce. She also owns Ohana Therapeutic Massage in downtown Hibbing.

VanBaalen said that an event like this has been on her mind for quite some time and that she found support for the idea with the Chambers Board of Directors. We field questions all the time about other health and wellness resources around, VanBaalen said. Many people dont seem to know the options available to them on the Range.

Billed as a bi-annual event, organizers are planning to host another similar event in the spring and are happy with the communitys response so far. Eighteen area health and wellness businesses are scheduled to participate. Event goers will find everything from traditional care providers, such as Essentia Health, St. Lukes and Choice Therapy, as well as coaches, trainers and mediation services. There will also be products to support healthy lifestyles, and more.

Plus there will be surprises. Well be giving out about 20-plus door prizes throughout the day, VanBaalen said.

Breakout sessions throughout the day will focus on a variety of wellness issues, ranging from movement to mental health. Its an opportunity for the community to learn more about options for all aspects of your health and wellness, said Hibbing Area of Commerce Sales and Event Coordinator Maegan Hoshal.

VanBaalen agreed, saying, Our goal is to have an event thats educational and engaging. There will be interactive demos and lots of information about all aspects of health and wellness physical, mental, community, environmental, etc.

One issue VanBaalen is passionate about is getting ahead of Seasonal Affective Disorder. She noted that its a common condition thats exacerbated by the decrease in Vitamin D and increase in holiday stress, which can lead to decreased activity, weight gain and various types of pain. Many people seem to fall into more unhealthy habits during the fall and winter months, VanBaalen said. If we can help expose them to different resources, we can give them a better opportunity for healthier, happier life.

Hibbing Health & Wellness Fair

Breakout Sessions

9:30 a.m. Healthy aging

10 a.m. Four steps to better posture

10:30 a.m. Mediation: an alternative way to cope with conflict

11 a.m. Movement, fuel, recovery: Roadblocks and simple ways to get started

11:30 a.m. Pilates is for every body

Noon Postpartum fitness: How to jump back into fitness

12:30 p.m. Detoxing: what it can do for you

1 p.m. Stem Cell Therapy-fact or fiction

More here:
Gettin' fit this fall | Free Press - Hibbing Daily Tribune

Eighteen-year-old Aisha Choudhary was just like any other adolescent eyes filled with dreams and a heart brimming with energy. The only difference was she was battling a rare genetic disease, Severe Combined Immune Deficiency (SCID). Diagnosed when she was six months old and undergoing medical treatment for years, she was iron-willed in playing the cards she was dealt.

Since one of the most effective cures for SCID is a stem cell transplant (grafting of the parent cells from which all blood cells develop), Aishas parents, Niren and Aditi, decided to opt for that treatment mode. But their cells were not a complete match with their daughters, and they had to look at external donors. However, due to a low number of voluntary, registered stem cell donors, Aisha could not get a compatible donor whose genetic markers were a close enough match to hers. With no other alternative treatment available, Aisha had a bone marrow transplant. But, it came with a side-effect that cost her life Pulmonary Fibrosis, a disease known to damage the lung tissues.

Aishas Choudhary's role has been played by Zaira Wasim in The Sky is Pink.

Aishas journey has been captured in The Sky is Pink, a recent Bollywood movie starring Priyanka Chopra, Farhan Akhtar, Zaira Wasim, and Rohit Saraf.

The 18-year-olds life story is mirrored in the experiences of many who await stem cell donation as treatment for blood-related illnesses likeleukemia, lymphoma, and sickle cell anemia every year. With very few individuals signing up as donors and the probability of finding a match being a dismal 0.0008 percent in India (against a lean 16 percent abroad), fatalities are mounting year on year.

However, in recent times, there has been one small break in the clouds a number of youngsters, non-governmental organisations, and medical professionals have come forward and are working to spread awareness about stem cell donation and motivate a larger number of people to register as donors.

The stem cells in a human body mainly comprise red blood cells, platelets, and white blood cells. These are found in the umbilical cord of newborns and in the peripheral or circulating blood and bone marrow.

A stem cell donation is as simple and painless as a blood donation.

Certain diseases like blood cancer and leukemia tend to destroy the bone marrow or affect its functioning.For these, treatments like chemotherapy and radiotherapy are tried initially. However, in some cases, they do not prove effective for a cure. The only recourse then is replacing the patients stem cells with those of a healthy person.

One of the main criteria for a successful transplant is a good match between the stem cells of the donor and those of the patient. Therefore, a donor registry will administer a cheek swab test (tissue samples extracted from the cheek) on all potential donors to match cell characteristics. This procedure of pairing generic markers is called Human Leukocyte Antigen (HLA) in medical terms.

A cheek swab test in progress.

Each potential donors tissue is entered in the registry and given an identification number after the test is done. If the registry finds a match at any point in time, the donor is contacted to initiate the transplant.

There are many organisations today that are leading the charge in saving the lives of people suffering from serious blood disorders like cancer, thalassemia, and anaemia.

For instance, Datri, an Ahmedabad-based NGO, is working to create a wide and diverse database of potential stem cell donors by organising donation drives. Founded in 2009 by two doctors and an engineer, the organisation focuses on conducting awareness campaigns and helping individuals sign up on its registry as a committed and voluntary benefactor.

The team of the NGO Datri.

The idea for Datri was initially born in the minds of doctors Nezih Cereb and Soo Young Yang, who run a laboratory, Histogenetics, for determining tissue matches between patients and donors. Since pairing tissue types is imperative for any stem cell transplant, and confronting a severe shortage of donors, the doctor duo would run from pillar to post to meet hospitals requirements. Working with a number of the hospitals in India, they realised just how acute the shortfall was in people willing to donate stem cells. They recognised the immediate need to create a donor registry here.

Soon after, Raghu Rajagopal, an engineer from BITS Pilani and Director of ready-to-eat venture Millets and More, connected with them and they decided to start Datri.

Today, the functioning of the registry, its maintenance, and even the substantial costs involved in conducting the HLA matching are taken care of by the lab. In the last 10 years, Datri has gotten over four lakh people to register as donors and has saved around 600 lives through successful transplantation.

Every day, about 40 people are diagnosed with blood disorders in India. Though these can be cured through a stem cell transplant from a genetically matched donor, there is only a 25 percent chance of finding a match from within the family. Others have no option but to rely on unrelated donors. But the chances of getting a match is anywhere between one in 10,000 and one in two million. There is an urgent need to rope in as many potential donors as possible, which is precisely what Datri is trying to do, Raghu explains.

Another organisation that is dedicated to fighting blood disorders with stem cell treatment is DKMS-BMST. It was formed through a joint venture between two renowned NGOs DKMS, which is one of the largest international blood stem cell donor centres globally, and the Bangalore Medical Services Trust (BMST).

The team of DKMS-BMST.

DKMS was founded in Germany in 1991 by businessman Dr Peter Harf, after he lost his wife to leukemia. BMST was born in 1984 from the vision of Dr Latha Jagannathan, a medical director and managing trustee. Since both organisations had a common goal to find a matching donor for every patient with a blood disorder, they decided to come together to achieve it.

A group of youngsters registering to be stem cell donors.

So far, more than 37,000 people in India have registered as potential donors after attending DKMS-BMSTs donor drives.

In highly populous countries like India, thousands of people are in need of stem cell transplants every year to survive. Though donating stem cells is a painless and non-invasive process, it remains a lesser-known medical concept in India, with only 3.6 lakh people willing to play a part in it. Besides, the chances of stem cells of people of the same ethnicity matching are higher than those of individuals from different ethnic backgrounds. But, it is due to sheer lack of awareness that India lags severely in stem cell donations, say experts.

Students taking a cheek swab test at one of the colleges in Bengaluru.

Dr Govind Eriat, a reputed hematologist and bone marrow transplant specialist, says,

With a major hurdle to stem cell donation in India proving to be the myths surrounding the subject, the youth are coming forward to deconstruct common misconceptions.

For instance, 21-year-old Tejaswini Patel, a student of Information Science at New Horizon College of Engineering, Bengaluru, has been busting the false ideas on stem cell donation, starting among her family and friends. She says,

She adds, with a notable sense of pride, In the last two years alone, around 400 students from my college have registered themselves as donors.

(Edited by Athirupa Geetha Manichandar)

Read more:
How Young India is fuelling the future of stem cell therapy and signing up to save lives - YourStory

By Express News Service

PURI:Stem cell therapy has offered hope to parents of children suffering from serious neurological disorders, said Dr Richa Bansod of Mumbai-based NeuroGen Brain and Spine Institute (BSI), here on Thursday.

She said latest advances in therapy hold great promise for autism in children. But they are suffering due to lack of awareness among parents.

Early treatment can significantly improve the condition and also effect recovery from the disorder, Dr Bansod said at a media conference here.

Citing one such example, she presented 16-year-old Anurag Champi of Bhubaneswar who has shown significant improvement after stem cell therapy. At present, the boy is being imparted speech therapy and necessary exercise to enable him for voice interface, said his mother Sangita.

In order to create awareness on the therapy among parents, a free autism treatment camp will be organised at Bhubaneswar on November 16. We are also providing free treatment to poor families at our Mumbai facility, said Dr Bansod.

Through neuro regenerative rehabilitation and stem cell therapy, brain stroke, brain and spine injuries caused by accident could be effectively treated, she added. Deputy Director of the institute Dr Nandini Gokulchandran was present.

Read the original post:
Stem cell therapy hope for autism patients - The New Indian Express

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Click to copy

IRVINE, Calif., Oct. 15, 2019 /PRNewswire/ -- AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today that the Companys ROOT of SKIN line of rejuvenating skincare products sold out in its tenth appearance on the Japanese home shopping channel QVC Japan.

ROOT of SKIN is AIVITAs proprietary skincare line for skin rejuvenation, made possible through the same proprietary knowledge and expertise used to develop its cutting-edge stem cell therapies. SourceCode Technology, the proprietary actives complex in ROOT of SKIN, contains the complete set of factors and supporting biological components present in young, healthy skin.

AIVITA Biomedical uses 100% of the proceeds from ROOT of SKIN sales to support the treatment of women with ovarian cancer.

Outstanding market traction, a product that truly works, and a benevolent use of proceeds, said Hans Keirstead, AIVITAs Chief Executive Officer. This sets the stage for global expansion of our ROOT of SKIN product line.

About ROOT OF SKIN

ROOT of SKIN is a rejuvenating line of skincare products fueled by an unrelenting pursuit for advancements in life-changing and life-saving treatments. Harnessing breakthroughs in stem cell therapy, AIVITA Biomedical developed a technology that does more than just boost regeneration. The patented actives complex SourceCode Technology renews, repairs and protects, just as your skin did at its youngest and healthiest stage. Rich with every biological component healthy skin needs for development, and free of any unnecessary ingredients. All proceeds support treatment of women with ovarian cancer.

About AIVITA Biomedical

AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its therapeutic pipeline and commercial line of skin care products.

View original content to download multimedia: http://www.prnewswire.com/news-releases/root-of-skin-skincare-products-sell-out-in-tenth-consecutive-appearance-on-qvc-japan-300938926.html

SOURCE AIVITA Biomedical, Inc.

Continue reading here:
ROOT OF SKIN Skincare Products Sell Out in Tenth Consecutive Appearance on QVC Japan - Associated Press

Sarah Ferguson is telling all on how shes fighting the signs of aging.

Ive had a lot of help to look like this at 60! the ex-wife of Prince Andrew told UKs Daily Mail newspaper on Thursday. Ferguson, nicknamedFergie, revealed shes a fan of non-invasive laser facelifts to keep her features youthful.

Ive started the laser treatment, but its not finished yet, said the proud mom of Princess Eugenie and Princess Beatrice. The collagen needs to rebuild. I hope it will all be done by my birthday.

PRINCESS MADELEINE, PRINCE CARL PHILIP OF SWEDENS CHILDREN LOSE THEIR ROYAL TITLES

The Duchess of York said she used the same treatmentlast year to prepare forPrincess Eugenies royal wedding. People magazine reported the laser lift is meant to work as a natural facelift, stimulating collagen and refinishing skin texture.

Sarah Ferguson, Duchess of York, and Princess Beatrice of York arrive for the royal wedding of Princess Eugenie and Jack Brooksbank at St George's Chapel in Windsor Castle, Windsor, Britain October 12, 2018. (Reuters)

I dont like the frozen look, said Ferguson, who turns the big 6-0 on Oct. 15. Im so animated and I like to be myself. I dont like the thoughts of needles and am very glad if I look well and happy Im really happy to be open about what Ive had done.

ELIZABETH HURLEY MET MEGHAN MARKLE BEFORE PRINCE HARRY DID: 'SHE WAS FANTASTIC'

Ferguson admitted that in the past, she has tried Botox. But these days, Ferguson insisted she relies on more minimally invasive treatments. Shes a fan of mesotherapy, which uses injections of vitamins, minerals and amino acids to boost collagen production. Ferguson said the treatment was the right choice for her after years of sun damage.

I need to repair the damage that was done on the beach when I was a child, she said. Its why I had the mesotherapy, the vitamin cocktail to hydrate and boost the skin.

After that therapy session in 2013, Ferguson said she had a facial thread lift, which involves inserting amesh of medically advanced threads under the skin, lifting the face and smoothing away fine lines.

KATE MIDDLETON'S BROTHER JAMES ANNOUNCES ENGAGEMENT TO FRENCH GIRLFRIEND ALIZEE THEVENET

Sarah Ferguson arrives for the wedding ceremony of Prince Harry and Meghan Markle at St. George's Chapel in Windsor Castle in Windsor, near London, England, Saturday, May 19, 2018. (AP)

ELTON JOHN WRITES QUEEN ELIZABETH SLAPPED HER NEPHEW ACROSS THE FACE IN FRONT OF HIM IN NEW BOOK

Its like garden trellising for sweat peas, said Ferguson. You insert the threads under the skin with a fine needle and they hold everything up. They also encourage collagen production. It takes a couple of months, then the sweat peas blood.

Before I had it done I thought, Oh, this is going to be so painful, but it wasnt bad, Ferguson continued. My skin responded well. I think if you look at photos of me after I had it done, I look much better.

CLICK HERE TO GET THE FOX NEWS APP

And her face wasnt the only thing Ferguson focused on.

According to the outlet, Ferguson traveled to the Bahamas earlier this year to have regenerative stem cell therapy on her feet.

PRINCESS BEATRICE ENGAGED TO EDOARDO MAPELLI MOZZI

Sarah Ferguson is getting candid about how she's fighting the signs of aging. (Reuters)

PRINCESS CHARLOTTE 'LOVES' UNICORNS, DAD PRINCE WILLIAM SAYS

I think my toes were ruined by all the riding I did when I was young, she explained, pointing to her big toe. They shaved the bone here and implanted stem cells, 20 million of them taken from my midriff, into my feet to make new cartilage. It takes about six months to heal but now I can walk in heels!

Visit link:
Sarah Ferguson gets candid on using Botox, laser facelifts and stem cell therapy for her feet - Fox News

Posted: Oct 8, 2019 / 09:45 AM GMT-0600 / Updated: Oct 10, 2019 / 01:15 PM GMT-0600

Stem cell therapy is one of the most successful procedures ever for solving joint pain. Your own bodys cells are injected back into the area where healing is needed: back, neck, hip, shoulder, etc. The new cells signal to body the need for regeneration, which starts to take place.

The treatment is a one-and-done injection, no surgery. Regenerative Medicine of Utah successfully treats many with stem cell therapy. One patient, John Dunn, was scheduled for knee replacement because of bone on bone pain. Before surgery he received an injection. Three months later and regenerated tissue was found in his knee joint. Six months later his knee was even better than that.

In just four weeks John was out of pain, but the body wasnt done healing. The cells continue signaling to the body the need for healing. Its usual to allow 12 months for the regeneration process to complete and reach its limit.

Making sure youre a candidateis important. Not everyone needs it. Many patients that end up being a candidateinitially thought they werent eligible. To know if youre a candidate schedulea consultation.

Right now, at Regenerative Medicine ofUtah an evaluation is $49 for the first 25 callers to (800)453-0286.

This article contains sponsored content.

See the original post here:
How the bodys cells can prevent the need for surgery - ABC 4

The Duchess of York, affectionately known as Fergie by the British public, decided to have pioneering regenerative stem cell therapy to be able to wear heels again. Fergie had to give up on her stilettos for a long time due to the excruciating pain she felt every time she tried to walk in them. And if she forced herself to wear high heels to mark important occasions she had to endure pain throughout the whole day.

Her feet caused Fergie trouble even during Princess Eugenies wedding last October.

Speaking to the Daily Mail, the Duchess of York said her feet were in such pain she felt relieved to be able to sit down in the pew and rest them for a while before Eugenie entered St Georges Chapel.

The source of the pain seemed to be her big toe, and now, thanks to regenerative stem cell therapy the Duchess is no longer in pain every time she opts to wear shows other than flats.

Fergie headed to the Bahamas to undergo stem cell therapy - an alternative to surgery which is yet to be proven fully safe and effective on humans and is therefore not widely available in the UK.

Speaking about her trip, she said: I went to the Bahamas in March to have the treatment.

I think my toes were ruined by all the riding I did when I was young.

They shaved the bone here and implanted stem cells 20 million of them taken from my midriff into my feet to make new cartilage.

It takes about six months to heal but now I can walk in heels!

READ MORE:The touching reason Beatrice will have British wedding

Fergie underwent a series of treatments during the years, including vitamin injections, organic fillers and botox - which she had a long time ago, when there was nothing else available.

Ahead of Eugenies wedding, Fergie underwent laser treatment to look her best.

Fergie attributed her glowing skin on October 12, the day of Princess Eugenies wedding, to her happiness.

But she also revealed she did seek the help of a professional to improve her natural beauty.

She said: The happiness was shining out of me because my daughter was getting married.

DON'T MISS

I was so glad. I love Jack. When Im passionate about anything, my eyes shine.

Above all, it was being joyful for Eugenie that made me look good.

But Id had some laser treatment on my face which helped, too.

Despite having used several techniques to stave off ageing, Fergie said there is one she is no longer going to have - Botox.

She said: I had Botox a long time ago when there was nothing else available.

I really dont like the frozen look.

Im so animated and I like to be myself.

I dont like the thought of needles and am very glad if I look well and happy.

Fergie also said she has stopped sunbathing after suffering two losses in her life which helped her realise she must take care of her skin just as well as any other organs.

Here is the original post:
Sarah Ferguson was in pain during Eugenies wedding - and needed treatment to recover - Express

The nation's leading regenerative training company, R3 Stem Cell, today announced the addition of world renowned Exosomes expert Dr. Ian White as a speaker at its training courses. He will be speaking at the October 18, 2019 course on Exosomes and there are still a few spots remaining!

LAS VEGAS, Oct. 10, 2019 /PRNewswire-PRWeb/ -- R3 Stem Cell announces it has added an exosome presentation to its upcoming regenerative training courses. The next course is October 18-19th, 2019 in Las Vegas with spots still open.

The speaker, Dr. Ian White PhD, is a world renowned expert on exosomes. He completed training at several Ivy League universities including Cornell, Harvard and Dartmouth. He currently serves as the Chief Scientific Officer at IMAC Regeneration Centers along with being President of Biofirma, which is a regenerative tissue manufacturing company.

Dr. White regular speaks worldwide on the topic of exosomes, stem cells and how they participate clinically to help optimize regenerative therapy outcomes. Exosome stem cell therapy is an amazing therapeutic option for patients, however, most providers do not understand the biologics and how to implement them properly.

According to R3 CEO David Greene, MD, MBA, "Obtaining knowledge on exosomes is important now, as patients are asking about them! Providers need to understand when to use them, how they work, and should have hands on experience with them. Our training course provides all of that experience."

R3 Stem Cell is the nation's leader in regenerative training, and provides a comprehensive education and hands on experience for providers to become their local leader. Along with offering the first rate exosome presentation, R3 will also have exosomes products on hand for attendees to try in a hands on setting.

Limited spots are still available for the upcoming October 18-19, 2019 training in Las Vegas. R3 is still offering $1000 off for the training, visit https://stemcelltrainingcourse.org/registration/ to sign up or call (844) GET-STEM.

See the original post:
R3 Stem Cell Announces Addition of World Renowned Exosome Expert Dr. Ian White to Training Course - Yahoo Finance